AlphaQuest LLC Sells 4,266 Shares of AtriCure, Inc. $ATRC

AlphaQuest LLC cut its holdings in AtriCure, Inc. (NASDAQ:ATRC) by 23.7% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,745 shares of the medical device company’s stock after selling 4,266 shares during the period. AlphaQuest LLC’s holdings in AtriCure were worth $450,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Acadian Asset Management LLC grew its holdings in AtriCure by 2,690.0% during the 1st quarter. Acadian Asset Management LLC now owns 195,582 shares of the medical device company’s stock valued at $6,304,000 after purchasing an additional 188,572 shares during the last quarter. First Bank & Trust bought a new position in AtriCure during the 2nd quarter valued at about $273,000. Osterweis Capital Management Inc. bought a new position in AtriCure during the 1st quarter valued at about $9,536,000. Envestnet Asset Management Inc. grew its holdings in AtriCure by 22.9% during the 1st quarter. Envestnet Asset Management Inc. now owns 56,656 shares of the medical device company’s stock valued at $1,828,000 after purchasing an additional 10,570 shares during the last quarter. Finally, Cresset Asset Management LLC bought a new position in AtriCure during the 1st quarter valued at about $365,000. 99.11% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, insider Justin J. Noznesky sold 3,000 shares of the business’s stock in a transaction on Friday, September 12th. The stock was sold at an average price of $36.30, for a total value of $108,900.00. Following the completion of the transaction, the insider directly owned 83,964 shares of the company’s stock, valued at approximately $3,047,893.20. The trade was a 3.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Sven Wehrwein sold 5,000 shares of the business’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $37.00, for a total value of $185,000.00. Following the completion of the transaction, the director directly owned 34,374 shares of the company’s stock, valued at approximately $1,271,838. The trade was a 12.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 17,952 shares of company stock valued at $655,633. 3.50% of the stock is currently owned by insiders.

AtriCure Price Performance

AtriCure stock opened at $35.44 on Thursday. The stock has a market cap of $1.76 billion, a price-to-earnings ratio of -46.03 and a beta of 1.59. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.94 and a quick ratio of 2.83. AtriCure, Inc. has a 1 year low of $28.29 and a 1 year high of $43.11. The firm has a 50-day moving average of $36.12 and a two-hundred day moving average of $33.93.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings results on Wednesday, October 29th. The medical device company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.10. AtriCure had a negative net margin of 7.27% and a negative return on equity of 4.20%. During the same period in the previous year, the firm posted ($0.17) earnings per share. AtriCure’s quarterly revenue was up 15.8% compared to the same quarter last year. AtriCure has set its FY 2025 guidance at -0.260–0.230 EPS. On average, research analysts forecast that AtriCure, Inc. will post -0.6 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on ATRC shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of AtriCure in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of AtriCure from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. Needham & Company LLC boosted their price objective on shares of AtriCure from $44.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, July 30th. Finally, BTIG Research set a $54.00 price objective on shares of AtriCure in a research report on Wednesday, July 30th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, AtriCure presently has an average rating of “Moderate Buy” and a consensus target price of $50.89.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.